PMC6378483_01
Patient's hands (a) before treatment with adalimumab, (b) 1 week after 80 mg loading dose, and (c) 24 weeks after initiation of adalimumab.
10.1177_2050313X19829620-fig1.jpg
PMC6378483_01_10.1177_2050313X19829620-fig1.jpg
fig1-2050313X19829620
Currently, at 70 years of age, her treatment plan comprised adalimumab 40 mg biweekly, alitretinoin 10 mg daily, ocular lubricant, and clobetasol propionate, with great response (see Figure 1).